INSUBCONTINENT EXCLUSIVE:
executive whose life sciences startup just hauled in $165 million in new funding.While the new money may have been raised under the looming
patients, and for potential causes of complex pneumonia, fungal infections and endocarditis, according to a statement from the
body leave traces of their DNA in blood, which are called microbial cell-free DNA (mcfDNA)
attention of SoftBank, which is backing the company through capital raised for its second Vision Fund.While SoftBank has been roundly
criticized for investing too much too soon (or too late) into consumer startups which have not lived up to their promise (notably with
implosions at Brandless, Zume and the potential catastrophe known as WeWork), its life sciences investing team has an impressive track
markets and with validated technology
validation behind it, the company raised its new cash to pursue rapid commercial adoption for its tests and to continue validating
applications of its technology while exploring new ones.Among the primary areas of exploration is the identification of new biomarkers,
company chief technology officer, Sivan Bercovici
sample and uses machine learning and DNA sequencing to recognize the microbial signatures
The company uses public databases that have records of over 300,000 pathogens
health systems, the company said.With that kind of reach, new investors, including General Catalyst and HBM Healthcare Investments, were
Nishar, senior managing partner at SoftBank Investment Advisers, in a statement
